Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease
Pediatric Blood & Cancer2012Vol. 60(4), pp. 653–658
Citations Over TimeTop 14% of 2012 papers
Suzette O. Oyeku, Monica Driscoll, Hillel W. Cohen, Rebecca Trachtman, Farzana Pashankar, Craig A. Mullen, Patricia J. Giardina, Nerissa Velazco, Andrew D. Racine, Nancy Green
Abstract
Pervasive concerns about HU safety exist, even among parents of current users. Varying knowledge among parents appears to be independent of their demographics, and is associated with HU use. Inter-institutional variability in parental knowledge and drug uptake highlights potentially potent site-specific influences on likelihood of HU use. Overall, these survey data underscore the need for strategies to bolster parental understanding about benefits of HU and address concerns about its safety.
Related Papers
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)